S&P 500   4,279.67 (-0.20%)
DOW   33,389.82 (-0.35%)
QQQ   360.50 (+0.62%)
AAPL   173.44 (+1.30%)
MSFT   317.68 (+0.61%)
META   304.67 (+1.49%)
GOOGL   132.85 (+1.52%)
AMZN   128.67 (+1.22%)
TSLA   250.02 (-0.08%)
NVDA   448.75 (+3.16%)
NIO   8.77 (-2.99%)
BABA   86.02 (-0.83%)
AMD   102.75 (-0.07%)
T   14.90 (-0.80%)
F   12.39 (-0.24%)
MU   68.01 (-0.03%)
CGC   0.78 (-0.15%)
GE   109.27 (-1.16%)
DIS   81.23 (+0.22%)
AMC   8.07 (+1.00%)
PFE   33.27 (+0.30%)
PYPL   59.28 (+1.40%)
NFLX   381.36 (+1.00%)
S&P 500   4,279.67 (-0.20%)
DOW   33,389.82 (-0.35%)
QQQ   360.50 (+0.62%)
AAPL   173.44 (+1.30%)
MSFT   317.68 (+0.61%)
META   304.67 (+1.49%)
GOOGL   132.85 (+1.52%)
AMZN   128.67 (+1.22%)
TSLA   250.02 (-0.08%)
NVDA   448.75 (+3.16%)
NIO   8.77 (-2.99%)
BABA   86.02 (-0.83%)
AMD   102.75 (-0.07%)
T   14.90 (-0.80%)
F   12.39 (-0.24%)
MU   68.01 (-0.03%)
CGC   0.78 (-0.15%)
GE   109.27 (-1.16%)
DIS   81.23 (+0.22%)
AMC   8.07 (+1.00%)
PFE   33.27 (+0.30%)
PYPL   59.28 (+1.40%)
NFLX   381.36 (+1.00%)
S&P 500   4,279.67 (-0.20%)
DOW   33,389.82 (-0.35%)
QQQ   360.50 (+0.62%)
AAPL   173.44 (+1.30%)
MSFT   317.68 (+0.61%)
META   304.67 (+1.49%)
GOOGL   132.85 (+1.52%)
AMZN   128.67 (+1.22%)
TSLA   250.02 (-0.08%)
NVDA   448.75 (+3.16%)
NIO   8.77 (-2.99%)
BABA   86.02 (-0.83%)
AMD   102.75 (-0.07%)
T   14.90 (-0.80%)
F   12.39 (-0.24%)
MU   68.01 (-0.03%)
CGC   0.78 (-0.15%)
GE   109.27 (-1.16%)
DIS   81.23 (+0.22%)
AMC   8.07 (+1.00%)
PFE   33.27 (+0.30%)
PYPL   59.28 (+1.40%)
NFLX   381.36 (+1.00%)
S&P 500   4,279.67 (-0.20%)
DOW   33,389.82 (-0.35%)
QQQ   360.50 (+0.62%)
AAPL   173.44 (+1.30%)
MSFT   317.68 (+0.61%)
META   304.67 (+1.49%)
GOOGL   132.85 (+1.52%)
AMZN   128.67 (+1.22%)
TSLA   250.02 (-0.08%)
NVDA   448.75 (+3.16%)
NIO   8.77 (-2.99%)
BABA   86.02 (-0.83%)
AMD   102.75 (-0.07%)
T   14.90 (-0.80%)
F   12.39 (-0.24%)
MU   68.01 (-0.03%)
CGC   0.78 (-0.15%)
GE   109.27 (-1.16%)
DIS   81.23 (+0.22%)
AMC   8.07 (+1.00%)
PFE   33.27 (+0.30%)
PYPL   59.28 (+1.40%)
NFLX   381.36 (+1.00%)
NASDAQ:AUTL

Autolus Therapeutics (AUTL) Stock Forecast, Price & News

$2.26
-0.07 (-3.00%)
(As of 10:20 AM ET)
Compare
Today's Range
$2.26
$2.35
50-Day Range
$2.32
$3.36
52-Week Range
$1.60
$3.54
Volume
38,976 shs
Average Volume
551,423 shs
Market Capitalization
$392.52 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.80

Autolus Therapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
234.8% Upside
$7.80 Price Target
Short Interest
Healthy
0.93% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.43mentions of Autolus Therapeutics in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.97) to ($0.86) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.28 out of 5 stars

Medical Sector

348th out of 968 stocks

Biological Products, Except Diagnostic Industry

54th out of 161 stocks


AUTL stock logo

About Autolus Therapeutics (NASDAQ:AUTL) Stock

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy, which is in preclinical trail targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate that is in a Phase I clinical trial for multiple myeloma. It also focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. The company was incorporated in 2014 and is headquartered in London, the United Kingdom.

AUTL Price History

AUTL Stock News Headlines

Autolus: CAR-T Therapy Looks Promising
Autolus Therapeutics: Innovating T Cell Cancer Treatments
Gold Could Be Heading for Record Highs - But How to Play It?
According to FX Empire, the gold forecast is now bullish, with support for a $3,000 target in 2024. The big question is how to play it. Some investors are discovering a unique gold investment alternative that sidesteps the major issues with gold mining stocks or physical gold.
Autolus Therapeutics Plc (NASDAQ: AUTL)
Gold Could Be Heading for Record Highs - But How to Play It?
According to FX Empire, the gold forecast is now bullish, with support for a $3,000 target in 2024. The big question is how to play it. Some investors are discovering a unique gold investment alternative that sidesteps the major issues with gold mining stocks or physical gold.
Autolus Therapeutics Appoints Robert Dolski CFO
Needham Sticks to Their Buy Rating for Autolus Therapeutics (AUTL)
Where Autolus Therapeutics Stands With Analysts
See More Headlines
Receive AUTL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Autolus Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

AUTL Company Calendar

Last Earnings
8/03/2023
Today
10/02/2023
Next Earnings (Estimated)
11/02/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:AUTL
Fax
N/A
Employees
399
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$7.80
High Stock Price Forecast
$12.00
Low Stock Price Forecast
$5.00
Forecasted Upside/Downside
+240.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

Net Income
$-148,840,000.00
Pretax Margin
-2,321.52%

Debt

Sales & Book Value

Annual Sales
$6.36 million
Book Value
$1.73 per share

Miscellaneous

Free Float
129,045,000
Market Cap
$397.73 million
Optionable
Not Optionable
Beta
1.54
10 Best Stocks to Own in 2023 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2023 and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Dr. Christian Martin Itin Ph.D. (Age 59)
    CEO & Director
    Comp: $2.68M
  • Dr. Martin Pule M.D. (Age 51)
    MBBS, Founder, Sr. VP & Chief Scientific Officer
  • Mr. Christopher Vann (Age 58)
    Sr. VP & COO
  • Mr. David Brochu (Age 67)
    Sr. VP & Chief Technical Officer
  • Mr. Brent Rice (Age 57)
    Sr. VP, Chief Commercial Officer & Site Head of US
  • Dr. Edgar E. W. Braendle M.D. (Age 63)
    Ph.D., Sr. VP & Chief Devel. Officer
  • Mr. Robert F. Dolski (Age 53)
    Chief Financial Officer
  • Ms. Olivia Manser
    Director of Investor Relations
  • Dr. Chris Williams (Age 43)
    Sr. VP of Corp. Devel.
  • Mr. Alexander Swan
    Chief HR Officer













AUTL Stock - Frequently Asked Questions

Should I buy or sell Autolus Therapeutics stock right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Autolus Therapeutics in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" AUTL shares.
View AUTL analyst ratings
or view top-rated stocks.

What is Autolus Therapeutics' stock price forecast for 2023?

5 brokers have issued twelve-month target prices for Autolus Therapeutics' shares. Their AUTL share price forecasts range from $5.00 to $12.00. On average, they expect the company's stock price to reach $7.80 in the next twelve months. This suggests a possible upside of 240.6% from the stock's current price.
View analysts price targets for AUTL
or view top-rated stocks among Wall Street analysts.

How have AUTL shares performed in 2023?

Autolus Therapeutics' stock was trading at $1.90 at the beginning of the year. Since then, AUTL shares have increased by 20.5% and is now trading at $2.29.
View the best growth stocks for 2023 here
.

Are investors shorting Autolus Therapeutics?

Autolus Therapeutics saw a increase in short interest during the month of September. As of September 15th, there was short interest totaling 1,610,000 shares, an increase of 17.5% from the August 31st total of 1,370,000 shares. Based on an average daily volume of 441,500 shares, the short-interest ratio is presently 3.6 days.
View Autolus Therapeutics' Short Interest
.

When is Autolus Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023.
View our AUTL earnings forecast
.

How were Autolus Therapeutics' earnings last quarter?

Autolus Therapeutics plc (NASDAQ:AUTL) posted its quarterly earnings results on Thursday, August, 3rd. The company reported ($0.26) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.22) by $0.04.

What ETF holds Autolus Therapeutics' stock ?

Range Cancer Therapeutics ETF holds 44,025 shares of AUTL stock, representing 1.33% of its portfolio.

What other stocks do shareholders of Autolus Therapeutics own?
When did Autolus Therapeutics IPO?

(AUTL) raised $125 million in an initial public offering on Friday, June 22nd 2018. The company issued 7,800,000 shares at $15.00-$17.00 per share. Goldman Sachs and Jefferies served as the underwriters for the IPO and Wells Fargo Securities and William Blair were co-managers.

What is Autolus Therapeutics' stock symbol?

Autolus Therapeutics trades on the NASDAQ under the ticker symbol "AUTL."

How do I buy shares of Autolus Therapeutics?

Shares of AUTL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Autolus Therapeutics' stock price today?

One share of AUTL stock can currently be purchased for approximately $2.29.

How much money does Autolus Therapeutics make?

Autolus Therapeutics (NASDAQ:AUTL) has a market capitalization of $397.73 million and generates $6.36 million in revenue each year. The company earns $-148,840,000.00 in net income (profit) each year or ($1.19) on an earnings per share basis.

How many employees does Autolus Therapeutics have?

The company employs 399 workers across the globe.

How can I contact Autolus Therapeutics?

Autolus Therapeutics' mailing address is FOREST HOUSE 58 WOOD LANE WHITE CITY, LONDON X0, W12 7RZ. The official website for the company is www.autolus.com. The company can be reached via phone at 442038296230 or via email at ir@autolus.com.

This page (NASDAQ:AUTL) was last updated on 10/2/2023 by MarketBeat.com Staff

My Account -